Imunon names Josh Blacher interim CFO as Jeffrey Church retires
The company disclosed the CFO transition in an 8-K reporting an event date of June 29, 2026, with Blacher installed through a master services agreement with Danforth Health.
Imunon, Inc. reported in an 8-K with a June 29, 2026 event date that Jeffrey Church informed the company of his intent to retire from the position of interim Chief Financial Officer, a position he had held since January of 2026, effective July 1, 2026.1 The filing itself is dated June 30, 2026, as shown in its signature page.
Church agreed to continue in a consulting role with the company, and the parties amended his consulting agreement, effective July 1, 2026, under which Imunon will pay him a monthly retainer of $10,000, terminable on 2 business days' notice.1 The company stated that Church's departure is due to retirement and is without any disagreements with management.1
Effective July 1, 2026, Imunon appointed Josh Blacher to serve as interim Chief Financial Officer under a master services agreement dated June 24, 2026 between the company and Danforth Health, Inc., described as a financial advisory services firm.1 Blacher will serve as the company's principal financial officer and principal accounting officer.1
Blacher, age 54, has been an employee of Danforth since September 2022, working as a chief financial officer in a consulting capacity for several life sciences companies, and has served as Chief Financial Officer of BullFrog AI Holdings, Inc. (Nasdaq: BFRG) since December 2024, among other roles.1 He previously served as Chief Business Officer at Inmed Pharmaceuticals from April 2018 to August 2019, Chief Financial Officer of Therapix Biosciences from April 2017 to April 2018, and Chief Financial Officer at Galmed Pharmaceuticals from October 2014 to March 2017.1
Under the agreement, Imunon will pay Danforth $475 per hour for Blacher's service as Chief Financial Officer.1 The company said the selection was not pursuant to any arrangement between Blacher and any other person, and that he has no family relationship with any director or executive officer and no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.